{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:51:52Z","timestamp":1761094312391,"version":"build-2065373602"},"reference-count":10,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To report our experience with the use of fidaxomicin (<jats:styled-content style=\"fixed-case\">FDX<\/jats:styled-content>), an oral macrocyclic antibiotic, in cancer patients with <jats:italic>Clostridium difficile<\/jats:italic> infection (<jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single\u2010center retrospective case series was conducted at The University of Texas <jats:styled-content style=\"fixed-case\">MD<\/jats:styled-content> Anderson Cancer Center. Patients with <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content> treated with <jats:styled-content style=\"fixed-case\">FDX<\/jats:styled-content> from May 2011 to January 2013 were identified via the pharmacy database. Clinical response and recurrence after <jats:styled-content style=\"fixed-case\">FDX<\/jats:styled-content> initiation were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010two patients were included, most of whom were male (55%) with a mean age of 58\u00a0years (range: 20\u201383\u00a0yrs). The most common underlying malignancies were nine patients with lymphoma (41%), seven with leukemia (32%), and six with solid tumors (27%). Indications for <jats:styled-content style=\"fixed-case\">FDX<\/jats:styled-content> included recurrent <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content> in 16 patients (72%) and failure of both metronidazole and oral vancomycin in 6 patients (28%). Nineteen patients (86%) were on concomitant antimicrobials during <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content> treatment. Clinical response to <jats:styled-content style=\"fixed-case\">FDX<\/jats:styled-content> was 91%, and overall sustained clinical response was 82%. <jats:styled-content style=\"fixed-case\">FDX<\/jats:styled-content> was well tolerated with no major adverse events that were <jats:styled-content style=\"fixed-case\">FDX<\/jats:styled-content> related or discontinuations due to drug\u2010related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In cancer patients, <jats:styled-content style=\"fixed-case\">FDX<\/jats:styled-content> is effective treatment for the first episode of <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content> after failure of standard therapies and treatment of recurrent <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>. This was interesting given the large number of high\u2010risk patients who continued to receive concomitant antimicrobial therapy, which is common in this immunocompromised patient population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.1479","type":"journal-article","created":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T04:33:05Z","timestamp":1409200385000},"page":"1220-1225","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Use of Fidaxomicin for Treatment of Relapsed <i>Clostridium difficile<\/i> Infections in Patients with Cancer"],"prefix":"10.1002","volume":"34","author":[{"given":"Amin","family":"Esmaily\u2010Fard","sequence":"first","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank P.","family":"Tverdek","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Crowther","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank S.","family":"Ghantoji","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier A.","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,28]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/651706"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/157489112801619674"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.5899"},{"volume-title":"Dificid (fidaxomicin) package insert","year":"2013","author":"Optimer Pharmaceuticals, Inc","key":"e_1_2_5_5_1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir404"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/668023"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05839.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/511870"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2009.08.004"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1479","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:17:12Z","timestamp":1761063432000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,28]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1002\/phar.1479"],"URL":"https:\/\/doi.org\/10.1002\/phar.1479","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2014,8,28]]},"assertion":[{"value":"2014-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}